The Motley Fool··Jonathan PoncianoMajor Fund Cuts Viridian Stake Before June FDA Decision on Lead Therapy
HighVista Strategies sold $7.08M of $VIR shares in Q1, reducing position ahead of June 30 FDA catalyst on veligrotug.
VRDNmonoclonal antibodyFDA approval